the best-selling drug in the world, to decline in the coming years? And can they trust Merck’s guidance on that decline? The problems with Gardasil relate entirely to sales of the vaccine in ...
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...
Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...
Jan 24 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of ...
Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck faces broader industry pressure as vaccine skeptic Robert F. Kennedy Jr. possibly next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback